INSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INSM is not a clean buy right now for a Beginner investor focused on the long term and wanting to deploy capital immediately. The stock has strong long-term bullish analyst support and impressive revenue growth, but the current technical setup is weak, pre-market price is slipping, insiders have been selling, and there is no fresh catalyst in the news. My direct view: hold off on buying today and wait for a clearer trend confirmation.
INSM is showing a short-term bearish setup. MACD histogram is below zero and still negative, moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and the stock is trading below the pivot at 139.20 with pre-market price at 136.33. RSI_6 at 32.56 is near oversold but not a strong reversal signal yet. Key levels: support at 134.21 and 131.13, resistance at 144.18 and 147.26. Overall, momentum is weak even though the stock is near support.
The main bullish narrative is Brinsupri's strong launch momentum and expanding market opportunity. Financially, Q4 2025 revenue surged 152.62% YoY and gross margin improved to 82.51%, showing major growth in the business.
There is no recent positive news in the last week. The company's Phase 2b brensocatib study in hidradenitis suppurativa missed efficacy endpoints and was discontinued, which removed a pipeline opportunity from the model. Insiders are selling, and selling has increased 193.33% over the last month. Technically, the stock is below key moving averages and showing bearish momentum.
Latest quarter: 2025/Q4. Revenue increased to $263.8M, up 152.62% YoY, which is very strong growth. Gross margin improved to 82.51%, also a positive. However, net income was still deeply negative at -$328.5M and EPS remained negative at -$1.54, though both improved year over year. This is a high-growth but still unprofitable company.
Wall Street is clearly bullish overall. Recent actions include multiple Buy/Outperform/Overweight ratings and higher price targets from Guggenheim, RBC, Raymond James, Barclays, Morgan Stanley, BofA, Mizuho, and Roth. The pros view: Brinsupri launch is de-risking the story and long-term growth looks strong. The cons view: a failed HS trial removed a pipeline asset, and the stock may already be pricing in a lot of optimism. Net analyst sentiment is positive, but the recent stock action and insider selling make the near-term setup less attractive.
